Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(tested or 100% immunogen sequence identity)
Ion exchange chromatography
IHC - Paraffin (1:100)
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Complement C5 antibody was raised against human C5, purified from plasma.
Recognizes complement component 5 (C5), a member of the complement system. The complement system consists of a tightly regulated network of proteins. Its activation leads to a sequential cascade of enzymatic reactions, resulting in opsonisation of the pathogens and their removal by phagocytes, as well as cell lysis. Three pathways have been described, the antibody-dependent pathway (classical pathway), the alternative pathway and the lectin activation pathway. The complement system plays a critical role in both innate and adaptive immune responses. It is also involved in tissue regeneration, tumor growth and some human pathologies. Complement component 5 is the initiator of the effector terminal phase of the complement system. C5 convertase cleaves C5 into C5a, a potent anaphylatoxin, and C5b, ultimately resulting in the formation of the multimeric membrane attack complex (MAC) together with the other components of the terminal pathway (C5b-C9). Gives a single arc when tested by immunoelectrophoresis (IEP) against human plasma. The identity has been confirmed by double diffusion against fresh human plasma and a known anti human C5.
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process.